A Phase 3, Single-arm, Open-label Extension of the Vericiguat VALOR Study in Pediatric Participants with Heart Failure due to Systemic Left Ventricular Systolic Dysfunction (VALOR EXT)

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-506210-40-00

Acronym

MK-1242-043

Enrollment

Registered

2024-03-12

Start date

2024-06-28

Completion date

2025-06-24

Last updated

2025-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure due to Systemic Left Ventricular Systolic Dysfunction

Brief summary

Number of Participants Who Experience an Adverse Event (AE), Number of Participants Who Discontinue Study Treatment Due to an AE

Detailed description

Change from baseline to Week 16 in N-terminal pro-brain natriuretic peptide (NT-proBNP)

Interventions

DRUGVericiguat

Eligibility

Sex/Gender

All

Age

0 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
Number of Participants Who Experience an Adverse Event (AE), Number of Participants Who Discontinue Study Treatment Due to an AE	—

Secondary

Measure	Time frame
Change from baseline to Week 16 in N-terminal pro-brain natriuretic peptide (NT-proBNP)	—

Countries

Belgium, Denmark, Finland, France, Germany, Hungary, Ireland, Italy, Netherlands, Poland, Portugal, Spain, Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026